The Challenges of Optimizing Biomarkers to Guide Clinical Decision Making

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2020 Mar 5

PMID 32129860

Citations 1

Authors

Stephen M Hewitt

Affiliations

Soon will be listed here.

Citing Articles

Usefulness of a novel device to divide core needle biopsy specimens in a spatially matched fashion.

Shiraishi T, Inui S, Inoue Y, Saito Y, Taga H, Kaneko M Sci Rep. 2020; 10(1):17098.

PMID: 33051506 PMC: 7555856. DOI: 10.1038/s41598-020-74136-3.

References

Stabile A, Delloglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N . Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. Eur Urol Oncol. 2019; 1(1):29-36. DOI: 10.1016/j.euo.2018.01.002. View

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz E . Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011; 35(7):1014-20. PMC: 3505676. DOI: 10.1097/PAS.0b013e31821e8761. View

Krohn A, Freudenthaler F, Harasimowicz S, Kluth M, Fuchs S, Burkhardt L . Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Mod Pathol. 2014; 27(12):1612-20. DOI: 10.1038/modpathol.2014.70. View

. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr. 2002; (30):5-15. View

Cooperberg M, Hilton J, Carroll P . The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011; 117(22):5039-46. PMC: 3170662. DOI: 10.1002/cncr.26169. View

Lotan T, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J . PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17(20):6563-73. PMC: 3195839. DOI: 10.1158/1078-0432.CCR-11-1244. View

Punnen S, Freedland S, Presti Jr J, Aronson W, Terris M, Kane C . Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2013; 65(6):1171-7. DOI: 10.1016/j.eururo.2013.03.058. View

Stone N, Crawford E, Skouteris V, Arangua P, Metsinis P, Lucia M . The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. J Urol. 2019; 202(2):264-271. DOI: 10.1097/JU.0000000000000204. View

Lotan T, Wei W, Ludkovski O, Morais C, Guedes L, Jamaspishvili T . Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Mod Pathol. 2016; 29(8):904-14. PMC: 4967011. DOI: 10.1038/modpathol.2016.88. View

10.

Yun J, Lee S, Ryu D, Park S, Park W, Joung J . Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer. Transl Oncol. 2018; 12(1):43-48. PMC: 6161410. DOI: 10.1016/j.tranon.2018.09.003. View

11.

Jamaspishvili T, Patel P, Niu Y, Vidotto T, Caven I, Livergant R . Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). J Natl Cancer Inst. 2020; 112(11):1098-1104. PMC: 7669224. DOI: 10.1093/jnci/djaa032. View

12.

Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015; 40(2):244-52. DOI: 10.1097/PAS.0000000000000530. View